Artemisinin

Artemisinin
Name	Artemisinin
Routes of administration	Intravenous; oral; intramuscular
Metabolism	Hepatic
Elimination half-life	Short (hours)

Artemisinin is a sesquiterpene lactone endoperoxide natural product originally isolated from the plant Qinghao (a traditional name for Artemisia annua). It revolutionized treatment of malaria in the late 20th century, earning recognition connected to the awarding of the Nobel Prize in Physiology or Medicine to researcher Tu Youyou. Artemisinin and its derivatives became central to global World Health Organization recommendations for combination therapy against Plasmodium falciparum and influenced public health policy in China, Vietnam, and Kenya.

History

The discovery narrative links Traditional Chinese Medicine texts attributed to Ge Hong and modern pharmacological screening programs such as Project 523 initiated during the Vietnam War-era collaboration between the People's Republic of China and allied scientists. Key actors include Tu Youyou, teams from the Academy of Military Medical Sciences (China), and scientists at the Shanghai Institute of Organic Chemistry. International dissemination involved agencies like the World Health Organization, nongovernmental organizations including Médecins Sans Frontières, and national programs in Tanzania and India. The international response linked academic groups at Harvard University, industrial partners such as Novartis for the development of artemisinin derivatives, and regulatory bodies like the European Medicines Agency.

Chemical Structure and Properties

Artemisinin is a sesquiterpene lactone featuring an unusual 1,2,4-trioxane (endoperoxide) bridge that is essential for activity; chemists at institutions such as the Max Planck Society and Scripps Research have elucidated synthetic analogs. Structural studies involved techniques developed at facilities like the Royal Society-affiliated laboratories and the National Institutes of Health-funded programs. Physical properties such as low aqueous solubility and thermal sensitivity informed formulation work at pharmaceutical firms including GSK and Sanofi. Synthetic organic chemists from ETH Zurich and Caltech contributed to total synthesis strategies and derivative optimization, while crystallographers using equipment from the European Molecular Biology Laboratory characterized conformational features.

Biosynthesis and Production

Biosynthetic pathways were elucidated by researchers at University of California, Berkeley, Max Planck Institute for Chemical Ecology, and the John Innes Centre, identifying precursors from the mevalonate and non-mevalonate pathways in Artemisia annua glandular trichomes. Metabolic engineering efforts in microbial platforms such as Saccharomyces cerevisiae and Escherichia coli were advanced by teams at Amyris and academic laboratories at University of California, San Diego and University of Cambridge to produce artemisinic acid intermediates. Agricultural initiatives in Kenya, China, and Vietnam scaled cultivation practices, while international development agencies including the Bill & Melinda Gates Foundation funded fermentation and semi-synthetic production projects with companies like Sanofi.

Mechanism of Action

Pharmacological models proposed by researchers at Imperial College London and Johns Hopkins University indicate activation of the endoperoxide bridge by iron sources such as heme released during parasite digestion of haemoglobin within the Plasmodium falciparum food vacuole. Resulting reactive oxygen species and carbon-centered radicals damage parasite proteins, membranes, and organelles; molecular targets implicated by proteomics studies at Cold Spring Harbor Laboratory and Karolinska Institutet include translational machinery and mitochondrial components. Insights from parasitologists at Liverpool School of Tropical Medicine and chemical biologists at University of Oxford refined the multi-target damage paradigm that explains rapid parasiticidal kinetics.

Clinical Uses and Efficacy

Artemisinin derivatives—such as artesunate, artemether, and dihydroartemisinin—were developed by collaborations involving Novartis, Kunming Pharmaceutical Corporation, and academic centers like Peking University. World Health Organization treatment guidelines endorse artemisinin-based combination therapies (ACTs) alongside partner drugs such as lumefantrine and piperaquine; large-scale clinical trials were conducted across Southeast Asia, Sub-Saharan Africa, and South America involving institutions like Mahidol University, Ifakara Health Institute, and London School of Hygiene & Tropical Medicine. Clinical endpoints measured by the New England Journal of Medicine and The Lancet include parasite clearance time, recrudescence rates, and reductions in severe malaria morbidity and mortality.

Resistance and Challenges

Emergence of reduced susceptibility was first documented in the Greater Mekong Subregion, with genetic markers in the parasite kelch13 gene identified by teams at Institut Pasteur and Wellcome Trust Sanger Institute. Public health responses involved coordination between World Health Organization, national ministries of health in Cambodia, Thailand, and Myanmar, and research consortia like the MalariaGEN network. Drug supply chain issues engaged agencies such as the Global Fund and manufacturers including Cipla. Surveillance efforts at Centers for Disease Control and Prevention and mathematical modeling groups at Princeton University examine spread dynamics, while alternative therapeutic strategies involve drug discovery programs at Novartis Institute for Tropical Diseases and vaccine candidates tested by GSK and Pfizer.

Safety and Pharmacology

Pharmacokinetic studies at Mayo Clinic and University of Oxford detail rapid absorption and short half-life, necessitating combination regimens; hepatic metabolism by cytochrome P450 isoforms was characterized by investigators at National Institutes of Health laboratories. Safety profiles reviewed by the European Medicines Agency and World Health Organization report generally favorable tolerability, with rare adverse events monitored in pharmacovigilance systems coordinated by Uppsala Monitoring Centre and national agencies such as the Food and Drug Administration. Drug–drug interaction assessments involved clinical pharmacology groups at Stanford University and University College London, informing dosing in special populations including pregnant women treated under protocols developed by UNICEF and maternal health teams at WHO.

Category:Antimalarial drugs